// App-Quantinova.ai

781.0 : Phase II trial of capecitabine +/- erlotinib in advanced colorectal cancer, with retrospective KRAS and primary tumor site analysis.

Researchers

Presenter

  • Daniel Adam Breadner

Principal Investigators

  • Stephen Welch

  • Denis Soulieres

  • Michael Susmoy Sanatani

  • Paul Klimo

  • Mary J. MacKenzie

  • Frances Whiston

  • Larry Stitt

  • Anne O'Connell

  • Mark David Vincent

Medical Centers

  • Schulich School of Medicine and Dentistry, London, ON, Canada

  • London Regional Cancer Centre, London, ON, Canada

  • Centre Hospitalier de LUniversite de Montreal (CHUM), Montreal, QC, Canada

  • LHSC London Regional Cancer Program, London, ON, Canada

  • Continuum Medical Care, West Vancouver, BC, Canada

  • London Health Sciences Center, London, ON, Canada

  • University of Western Ontario, London, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • KRAS proto-oncogene, GTPase

  • ZFP36 Ring Finger Protein Like 1

Drug/Treatment

  • Capecitabine

  • Erlotinib hydrochloride

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved